Opinion

Video

Clinical Pearls for Clinicians Treating Fibromyalgia

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

This is a video synopsis/summary of a panel discussion involving Philip J. Mease, MD.

Fibromyalgia may raise concerns for physicians regarding time consumption and emotional burden. Addressing these concerns requires upfront communication, explaining the neurobiology behind fibromyalgia to reduce stigma, particularly associated with psychological perceptions. With improved treatment approaches, managing fibromyalgia becomes more rewarding, especially when patients respond well to their treatment regimen. When patients have comorbid conditions, such as autoimmune diseases like rheumatoid arthritis or lupus, it's crucial to control both conditions concurrently. Employing current medications, biologics, and targeted synthetic disease-modifying drugs to manage inflammation and symptoms is essential. Simultaneously, acknowledging the presence of central sensitization or fibromyalgia is vital, fostering acceptance through patient-friendly language. Using terms like "central sensitization" can mitigate the stigma around fibromyalgia. Collaboratively pursuing nonpharmacological approaches alongside prescribed treatments enhances patient acceptance and makes the overall treatment approach more rewarding for both the physician and the patient.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

Related Videos
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
© 2024 MJH Life Sciences

All rights reserved.